AVALO THERAPEUTICS, INC.

Analyst Reco. Avalo Therapeutics, Inc.

Equities

AVTX

US05338F3064

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-01 EDT			5-day change	1st Jan Change
16 ^USD	-6.54%		+12.68%	+75.82%

04-17	North American Morning Briefing : Stock Futures -2-	DJ
04-16	Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	04-16	MT
Oppenheimer Downgrades Avalo Therapeutics to Perform From Outperform, Removes $10 Price Target	23-06-27	MT
Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept	23-06-27	MT
RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier	23-05-10	MT
Jefferies Downgrades Avalo Therapeutics to Underperform From Hold, Lowers Price Target to $3 From $4.50	23-02-08	MT
Oppenheimer Adjusts Avalo Therapeutics Price Target to $10 From $17, Maintains Outperform Rating	22-11-09	MT
Oppenheimer Adjusts Avalo Therapeutics Price Target to $17 From $5, Maintains Outperform Rating	22-08-08	MT
RBC Cuts Price Target on Avalo Therapeutics to $17 From $21, Maintains Outperform Rating, Speculative Risk Qualifier	22-08-05	MT
RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept	22-07-11	MT
RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk With Minimal Safeguards,' Keeps Outperform-Speculative Risk Rating	22-05-06	MT
Jefferies Downgrades Avalo Therapeutics to Hold from Buy, Adjusts Price Target to $0.75 from $5	22-03-03	MT
RBC Cuts Price Target on Avalo Therapeutics to $4 From $5, Maintains Outperform Rating, Speculative Risk Qualifier	22-03-03	MT
Oppenheimer Adjusts Avalo Therapeutics PT to $5 From $7, Maintains Outperform Rating	21-11-10	MT
AVALO THERAPEUTICS : RBC Initiates Avalo Therapeutics With Outperform Rating, Speculative Risk Qualifier, Sets Price Target at $6	21-09-24	MT
CERECOR : Cantor Fitzgerald Initiates Coverage on Cerecor With Overweight Rating, $7 Price Target	21-06-04	MT
CERECOR : Oppenheimer Adjusts Cerecor PT to $7 From $9 on Q1 Results and Ahead of Top-Line Data, Maintains Outperform Rating	21-05-24	MT
CERECOR : Maxim Upgrades Cerecor to Buy from Hold, Sets $7 Price Target	21-04-21	MT
CERECOR : Jefferies Initiates Cerecor at Buy with $4 Price Target	21-04-20	MT
CERECOR : Oppenheimer Adjusts Cerecor PT to $9 From $10, Maintains Outperform Rating	20-11-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer